Added to YB: 2026-06-11
Pitch date: 2026-06-09
UCB.BR [neutral]
UCB SA
-0.11%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Market Cap
EUR 49.9B
Pitch Price
EUR 264.70
Price Target
N/A
Dividend
0.55%
EV/EBITDA
19.06
P/E
32.67
EV/Sales
6.44
Sector
Pharmaceuticals
Category
growth
UCB (UCB Belgium): Bimzelx is building a case to become one of the defining assets
UCB.BR (update): Bimzelx became 1st biologic to beat AbbVie's Skyrizi head-to-head in psoriatic arthritis (BE BOLD: ACR50 49.1% vs 38.4%, faster onset). 5 indications, 50+ countries, multiple superiority studies. Diversified growth via Rystiggo, Zilbrysq, Fintepla. Consensus raising Bimzelx estimates; strong EU biopharma growth platform.
Read full article (2 min)